Cloud provider CoreWeave faces investor lawsuits over capacity claims just as Nvidia doubles down with a major investment, placing the company at the center of a high-stakes debate on AI infrastructure's future.
Bio-Techne (TECH) gains market attention with the launch of its Cultrex Synthetic Hydrogel, a key innovation for 3D cell research. While the product debut coincides with recent share price strength, longer-term returns tell a more complex story for investors.
Shares of building technologies giant Johnson Controls International have surged over 60% in the past year, dramatically outperforming the broader market. As the stock hovers near $123, investors are grappling with a critical question: does the current price reflect the company's true value, or has momentum outpaced fundamentals? A deep dive into valuation metrics suggests caution may be warranted.
Johnson & Johnson's oncology portfolio gains momentum with new clinical data for prostate cancer drug Erleada and a broader FDA label for multiple myeloma therapy Darzalex Faspro, reinforcing its competitive stance in key cancer markets.
As hyperscalers like Amazon prepare to report earnings, the focus is shifting from quarterly sales to massive capital investments in AI infrastructure and strategic partnerships with GPU-as-a-service providers.
As AI agents flock to a dedicated social platform, creating their own cultures and discussing independence, tech billionaire Bryan Johnson warns of unforeseen consequences, comparing the phenomenon to a mirror of humanity's own impulses.
Personal finance expert Dave Ramsey joins critics in dismissing the concept of a 50-year home loan, arguing it offers minimal monthly savings while drastically increasing long-term costs and risks for homeowners.
Alpha Metallurgical Resources (AMR), the largest U.S. metallurgical coal producer, is drawing investor attention not for explosive growth, but for a fortress balance sheet and a disciplined capital return strategy that insulates it from industry downturns.
Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.
Argan, Inc., a specialized engineering and construction firm, is drawing investor attention with its robust financial performance, zero-debt balance sheet, and strategic positioning in the evolving energy sector. Despite a premium valuation, its record backlog and cash-generating prowess present a compelling bull case.
Avery Dennison (AVY), the often-overlooked materials science giant, is drawing investor attention with its pivot to high-margin digital identification solutions and a rock-solid financial profile. With intelligent labels driving growth and a dividend that has increased for 15 consecutive years, the company presents a case for resilient, innovation-led expansion.
Cipher Mining Inc. (CIFR), once a traditional cryptocurrency miner, has rapidly transformed into a key developer of industrial-scale data centers, capitalizing on the insatiable power demands of artificial intelligence. With a portfolio exceeding 3 gigawatts, primarily in power-rich West Texas, the company is now building the physical backbone for tech giants. This strategic pivot, however, raises critical questions about capital allocation and the sustainability of the AI infrastructure rush.
As the AI infrastructure race intensifies, a critical bottleneck is emerging: memory. With demand for high-bandwidth memory (HBM) skyrocketing, Micron Technology finds itself at the center of a new investment thesis, drawing comparisons to the early days of Nvidia's AI-driven ascent.
A North Carolina mother, mourning the loss of her daughter and the young woman's boyfriend in a head-on collision, speaks out against what she perceives as a culture of irresponsibility glorified in award shows and a justice system that failed to prevent a preventable tragedy.
As AI infrastructure scales, reliability becomes paramount. Credo Technology Group, once a niche connectivity player, is now seeing explosive growth as its solutions become critical to preventing costly failures in hyperscale data centers. With revenue soaring over 270% and margins expanding, the debate is whether Credo is a cyclical beneficiary or the foundational 'toll road' of modern AI computing.
AerCap Holdings N.V., the world's largest aircraft lessor, is drawing renewed attention from value investors. Despite geopolitical headwinds and a cyclical reputation, its robust cash flows, industry dominance, and compelling valuation present a strong case for a rerating, as global travel demand outpaces constrained aircraft supply.
A deep dive into the bullish investment thesis for Inter & Co (INTR), which argues the integrated financial platform is significantly undervalued compared to regional giant Nubank, with its ambitious growth plan setting the stage for potential upside.
Amid a volatile market, specialty insurer Palomar Holdings (PLMR) presents a compelling growth story. With a disciplined underwriting strategy, robust risk management, and a track record of doubling profits every few years, the company trades at multiples that may significantly undervalue its consistent execution and expansion potential.
Amidst market frenzy for AI, a bullish case is building for Vital Farms. Analysts highlight its premium brand resilience, predictable growth, and surprising insulation from the egg price swings that hammer competitors.
A significant institutional options trade on Abbott Laboratories (ABT) signals strong confidence in the healthcare giant's legal resilience and valuation floor, presenting a unique risk/reward opportunity for investors.
